Peptide · Fact sheet

Setmelanotide

Also known as Imcivree · RM-493

Imcivree has FDA-approved weight-reduction indications for acquired hypothalamic obesity from age 4 and specified genetic obesity conditions from age 2. It is not approved for general obesity.

FDA approved for specific usesStrong human evidence for approved uses

What is Setmelanotide?

Setmelanotide is a synthetic cyclic peptide that activates the melanocortin-4 receptor, a key part of the brain pathway regulating hunger and body weight.

The approved populations have specific genetic or acquired hypothalamic disorders; results cannot be transferred to common polygenic obesity.

Benefits & claims

It shows why the cause of obesity matters: the approved uses involve specific genetic conditions or acquired hypothalamic injury, rather than general weight management.

Research continues in additional rare syndromic forms of obesity, but each requires its own evidence and regulatory review.

What the evidence supports

  • Pivotal studies observed clinically important weight reduction in some people with rare MC4-pathway disorders.
  • The treatment can also reduce hunger in responsive patients, but response varies by genetic condition and person.
Research areas
  • POMC, PCSK1, and LEPR deficiency obesity
  • Bardet-Biedl syndrome
  • Other rare hypothalamic or syndromic obesity conditions
  • Hunger and hyperphagia outcomes
  • Additional genetically or anatomically defined obesity syndromes

Dosage & frequency

Product-specific label information

Imcivree dosing depends on the cause of obesity, age, weight, and renal function. The acquired hypothalamic-obesity starting amount differs from genetic-obesity treatment.

Imcivree: genetic or syndromic obesity

Patients age twelve years and older with labeled BBS, POMC, PCSK1 or LEPR-related obesity

Amount
2 mg for two weeks; recommended maintenance 3 mg
Frequency
Once daily
Route studied or labeled
Subcutaneous

Disease-specific eligibility; younger patients have different starting amounts.

Imcivree: acquired hypothalamic obesity

Adults and patients age six years and older with acquired hypothalamic obesity

Amount
Start 0.5 mg for two weeks; titrate to recommended 3 mg maintenance
Frequency
Once daily
Route studied or labeled
Subcutaneous

Patients age four to below six have weight-based maintenance; renal adjustments apply.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The label limits treatment to specified hypothalamic, syndromic, or monogenic causes of obesity.

Interactions & precautions

  • The label describes low interaction potential in vitro but states that clinical drug-drug interaction studies have not been conducted.

What is still unresolved

  • The product is not established for general polygenic obesity.

Side effects & risks

  • The label warns about depression and suicidal thinking, sexual-arousal effects, serious hypersensitivity, and skin darkening or changes in existing moles.
  • Common adverse reactions include skin hyperpigmentation, injection-site reactions, nausea, headache, gastrointestinal symptoms, depression, and spontaneous erections.
  • The label adds warnings about acute adrenal insufficiency in acquired hypothalamic obesity and sodium imbalance when central diabetes insipidus is also present.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Human trials support weight and hunger outcomes in small rare-disease populations. The evidence is meaningful for those exact pathway disorders and does not establish benefit for common obesity.

Studies

What do the human studies show?

Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.

For this question, the FDA decision below is the main source. It explains the evidence behind the approval and its limits.

What these results can and cannot tell us

Does Imcivree include acquired hypothalamic obesity?

The label distinguishes acquired hypothalamic obesity from age 4 and specified genetic conditions from age 2.

Limit: Approval does not extend to general obesity or every genetic variant.

Check the sources: FDA Imcivree prescribing information (checked 2026-09-18)

What is approved, and for whom?

United States records selected for the questions above; not a complete label or a worldwide approval inventory.

Imcivree: Acquired hypothalamic obesity

Subcutaneous injection · Adults and children aged at least 4 with acquired hypothalamic obesity

approved — Not an indication for general obesity. Acquired hypothalamic obesity has specific warnings.

Exact linked source and stated indication only; not an exhaustive regulatory search.

Read the original source · Source checked: 2026-09-18

Imcivree: Specified genetic obesity

Subcutaneous injection · Age 2+ with BBS or specified genetically confirmed POMC, PCSK1 or LEPR deficiency

approved — Genetic eligibility and limitations are defined in the label; not all variants qualify.

Exact linked source and stated indication only; not an exhaustive regulatory search.

Read the original source · Source checked: 2026-09-18

Compare research questions · Submit a source-based correction

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Positive account · patient survey

Feeling full for the first time

A caregiver in CADTH's stakeholder survey described their child feeling less constantly hungry, choosing smaller portions, losing weight and feeling better about herself.

Reported use in this account

Product
Setmelanotide
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Hunger changes first noticed after one to two months; total duration not stated

Selected patient-group responses are not a controlled assessment or a prediction for other causes of obesity.

Read the original accounts
Positive account · patient survey

Less food preoccupation, more school engagement

Caregiver D described reduced food preoccupation, weight loss, better energy and more attention to school and friends during her daughter's trial participation.

Reported use in this account

Product
Setmelanotide clinical-trial treatment
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Less than one year

The interview was advocacy input supporting access, not independent verification of efficacy.

Read the original accounts

Approval status

The Imcivree label covers acquired hypothalamic obesity from age 4, and specified POMC, PCSK1 or LEPR deficiency or Bardet-Biedl syndrome from age 2. These are distinct populations; general obesity remains outside the indication.

Approved uses

  • Long-term reduction of excess body weight in eligible people age 2 and older with specified POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome
  • Weight reduction and maintenance in acquired hypothalamic obesity from age 4

FDA approved for rare genetic obesity indications

Imcivree has distinct age and diagnosis criteria: acquired hypothalamic obesity from age 4, and specified genetic obesity conditions from age 2. General obesity is not included.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term outcomes beginning in very young children
  • Which additional rare obesity disorders will respond
  • How benefits and risks compare across the small, genetically distinct approved groups
  • Effects in common obesity, where the drug is not indicated

Summary

Setmelanotide targets a particular hunger-signaling pathway. Its approved use depends on the exact diagnosis and labeled population, including specified genetic conditions and acquired hypothalamic obesity.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Imcivree

    Distinct acquired hypothalamic and genetic obesity indications, age limits and warnings.

  2. fdaFDA orphan-drug approvals: setmelanotide

    Official approval history for the rare genetic obesity indications.

  3. pubmedPhase 3 POMC and LEPR deficiency trials

    Pivotal human trials in severe obesity caused by POMC or LEPR deficiency.

  4. pubmedPhase 3 Bardet-Biedl syndrome trial

    Randomized trial supporting the Bardet-Biedl syndrome indication.

How we assess sources · Suggest a correction